Clearmind Medicine Inc. (CMND) stock
CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Score 5/30
$4.53−0.09 (-1.95%)
Close on Nov 13, 2026Market cap $716.08KP/E –Yield –
Clearmind Medicine r&d expenses
Research and development expenses are spending on new products and technology.
Clearmind Medicine's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.30M, up 8.2% year over year. For fiscal 2025 it was $2.06M, up 48.7% from the year before. The highest annual figure on record is $3.08M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.06M | +48.7% |
| FY2024 | Oct 31, 2024 | $1.38M | -10.5% |
| FY2023 | Oct 31, 2023 | $1.54M | -49.9% |
| FY2022 | Oct 31, 2022 | $3.08M | +550.5% |
| FY2021 | Oct 31, 2021 | $473.65K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $588.96K | -18.5% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $646.71K | +43.1% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $640.49K | +38.8% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $420.18K | -13.6% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $723.05K | +109.0% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $451.86K | +39.9% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $461.44K | +3520.3% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $486.49K | +29.7% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $345.88K | +31.0% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $322.96K | +1.7% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $12.75K | -97.8% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $375.07K | -67.7% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $263.95K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $317.57K | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $587.63K | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | $1.16M | – |
See a number that looks wrong?